drug
Zurnai
Marketedupdated 3mo agoby Purdue Pharma LP
Approvedcommunity read0 votes
indications
investigational
Major Depression
all catalysts(0)
nothing on the calendar yet
Trials studying Zurnai
- phase1Pharmacokinetic (PK) Evaluation of Nalmefene Formulations
- phase1Nalmefene Implant in Healthy Subjects
- phase2TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis
- phase1Pharmacodynamic Evaluation of Intranasal Nalmefene
- phase1Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
- phase1An Evaluation of The Absolute Bioavailability of TH104
- —Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence
- phase1Pharmacokinetic Evaluation of Intranasal Nalmefene
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 10, 2038
~11.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Aug 4, 2042method-of-use (U-4182)US 12290596
- Jul 10, 2038formulationUS 11458091
FDA exclusivities (1)
- May 22, 2026NPNP
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that